Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.36 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.36 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9066818 | 0.82 | BCHE (0.43) | LMNAKMT2AALDH1A1 | |
| SCHEMBL5216010 | 0.81 | TDP1 (0.50) | TDP1LMNASMN1; SMN2MAPK1HIF1A | |
| SCHEMBL1087819 | 0.72 | TDP1 (0.45) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL1087816 | 0.72 | TDP1 (0.45) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL1088261 | 0.72 | TDP1 (0.45) | TDP1LMNAMAPK1HIF1ASLC6A2 | |
| SCHEMBL16802312 | 0.70 | TDP1 (0.50) | TDP1LMNASMN1; SMN2KMT2AALDH1A1 | |
| SCHEMBL582774 | 0.69 | TDP1 (0.70) | TDP1LMNASMN1; SMN2MAPK1HIF1A | |
| SCHEMBL10974892 | 0.68 | LMNA (0.66) | TDP1LMNASMN1; SMN2MAPK1HIF1A | |
| SCHEMBL137486 | 0.68 | TDP1 (0.83) | TDP1LMNASMN1; SMN2MAPK1HIF1A | |
| SCHEMBL6935004 | 0.67 | TDP1 (0.68) | TDP1LMNASMN1; SMN2MAPK1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110257396-A1 | PROCESS FOR THE MANUFACTURE OF CIS(-)-LAMIVUDINE | LUPIN LIMITED (IN) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257396-A1 | PROCESS FOR THE MANUFACTURE OF CIS(-)-LAMIVUDINE | TYMS, TYMP, SAMHD1 | TDP1 1469/4885LMNA 643/4885SMN1; SMN2 3179/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.